The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ascendis Pharma A/S (NASDAQ:ASND) reported first-quarter 2026 results highlighted by the U.S. FDA approval of its third TransCon product, YUVIWEL, and continued growth across its rare endocrine ...

Ascendis Pharma has ended internal development of its IL-2 candidate, pivoting away from oncology and calling time on an ...

Leptin a Potential Target to Reduce CVD Risk in CKD-MBD TransCon PTH is an investigational once-daily long-acting prodrug of parathyroid hormone (PTH[1-34]) designed to restore physiologic levels of ...

Credit: Getty Images. The phase 3 PaTHway trial included 82 adults with chronic hypoparathyroidism. Positive topline results were announced from a phase 3 trial evaluating the efficacy and safety of ...

SHANGHAI, March 31, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, announced on March 30 that it had successfully completed its ...

- In non-clinical models, a single dose of TransCon™ TLR7/8 Agonist activated critical innate and adaptive immune mechanisms, providing sustained modulation of tumor microenvironments with low ...

LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody (mAb), combines tumor microenvironment (TME) targeted delivery (PD-L1) and a single biological high potency effector (CD47) ...